AstraZeneca moves US court against Aurobindo Pharma

Hyderabad: Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg).

In a petition filed in the United States District Court for the District Court of New Jersey on May 15, AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.

Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations).